Noah L. Rosenberg - 25 Nov 2025 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Reporting relationship: CMO
Issuer ticker: VRCA
Reported as of: 25 Nov 2025
Net transaction value: +$10,000
SEC form: 4
Accepted by SEC: 25 Nov 2025, 19:00:16 UTC
Prior SEC filing: 26 Mar 2025
Next SEC filing: 09 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Jayson Rieger, Attorney-in-Fact

Key filing fact

Noah L. Rosenberg filed Form 4 for Verrica Pharmaceuticals Inc. (VRCA) on 25 Nov 2025.

Key facts

This page summarizes Noah L. Rosenberg's Form 4 filing for Verrica Pharmaceuticals Inc. (VRCA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 25 Nov 2025, 19:00.

Change

Previous filing in this sequence was filed on 26 Mar 2025.
Current net transaction value: +$10,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001579649 Primary reporting owner

Rosenberg Noah L.

Relationship: CMO
Address: C/O VERRICA PHARMACEUTICALS INC., 44 W. GAY ST., SUITE 400, WEST CHESTER
Signature: /s/ Jayson Rieger, Attorney-in-Fact
Signature date: 25 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VRCA transaction

Common Stock

Purchase

Transaction value: $10,000
Shares: +2,357
Change %
Price: $4.24
Shares after: 2,357
Date: 25 Nov 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VRCA transaction Derivative

Series C Warrant (right to buy)

Purchase

Transaction value
Shares: +589
Change %
Price
Shares after: 589
Date: 25 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 589
Exercise price: $6.32
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Immediately exercisable.

Footnote F2

The reported securities are included within 2,357 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.